Novartis Advances Novel Kidney Disease Therapy Iptacopan
Data Suggest Promise For Lead Nephrology Asset
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
You may also be interested in...
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.
INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.